The United States Patent and Trademark Office (USPTO) has issued patent US12584907B1, titled "Hydrogel for organoid patterning and vascularization." This patent covers a novel cell scaffold composed of methacrylated hyaluronic acid (HAMA) and dopamine-modified hyaluronic acid (HA-Cat). The scaffold is designed to regulate organoid patterning and vascularization, specifically enabling the co-culture of spinal cord spheroids or organoids with blood vessel spheroids to create blood-spinal cord barrier models. The patent was granted on March 24, 2026, to The Florida State University Research Foundation, Inc.

This patent grant represents a new intellectual property development in the field of regenerative medicine and biomedical research. While not a regulatory rule imposing obligations, it signifies a technological advancement that may influence future research and development in areas such as spinal cord injury treatment, drug testing platforms, and the creation of in vitro disease models. Companies and research institutions operating in biotechnology, pharmaceuticals, and medical device development should be aware of this patent, as it may impact their freedom to operate or provide opportunities for licensing and collaboration.